Menu
BioCentury This Week
Podcast image
Ep. 68 - Drug Pricing Pressure, Plus European Deal Trends
26 mins; July 19, 2021
Ep. 67 - Aduhelm: a Tangled Plot; Plus, INTREPID Pandemic Planning
32 mins; July 12, 2021
Ep. 66 - Biotechs hit 3Q with Coolers Full of Cash; plus Distillery on Tap
21 mins; July 06, 2021
Ep. 65 - Optimism for Intellia's CRISPR Breakthrough, Concerns about Aduhelm
22 mins; June 28, 2021
Ep. 64 - Amyloid Analysis: Stress Testing FDA's Logic on Surrogate Endpoint
18 mins; June 23, 2021
Ep. 63 - Woodcock, Noubar and Genmab’s dealmaking: A BioCentury Podcast
24 mins; June 21, 2021
Ep. 62 - Reflecting on the Implications of Aduhelm's Approval: A BioCentury Podcast
18 mins; June 14, 2021
Ep. 61 - Dissecting FDA's Aducanumab Decision
25 mins; June 07, 2021
Ep. 60 - D-Day for Aducanumab: What's at stake
15 mins; June 02, 2021
Ep. 59 - KRAS to the Future; plus ARPA-H & EGFR
23 mins; June 01, 2021
Ep. 58 - LAG3 Before You Leap; plus BEE21, G20 Highlights
24 mins; May 24, 2021
Ep. 57 - Financing Scandinavia; plus IP Waivers, Long Covid & AAV Pays
28 mins; May 10, 2021
Ep. 56 - FDA’s ODAC Bind; plus NK Cell Engagers and Company Creation in Europe
20 mins; May 03, 2021
Ep. 55 - German Plays Deliver on Data, plus Accelerated Approval on Trial
19 mins; April 26, 2021
Ep. 54 - Patient Groups’ Pandemic Pain; plus Voters’ Rights and Synthetic Lethality
25 mins; April 19, 2021
Ep. 53 - Competence & Continuity at CDER; plus BIO 3.0, AACR and 2Q Preview
23 mins; April 12, 2021
Ep. 52 - Memories of John Martin, plus AACR's Hot Targets & Bio€quity Europe Preview
23 mins; April 05, 2021
Ep. 51 - Abernethy & the Obvious at FDA; Plus CEPI & EpimAb
18 mins; March 29, 2021
Ep. 50 - FTC & the Zombie Pharma Dinosaurs; Plus: RIP José Baselga, NCATS & SPACs
18 mins; March 22, 2021
Ep. 49 - Vaccine Vexed; Plus Assessing Lilly's Alzheimer's Data & PDUFA Preview
20 mins; March 15, 2021
Ep. 48 - New Modality Deep Dive; plus Sharpless Speaks & Five Prime Scores
20 mins; March 08, 2021
Ep. 47 - Whither Woodcock; plus Refresh for German Biotech & Modalities to Market
25 mins; March 01, 2021
Ep. 46 - Pipeline plays for BMS, Rigel; plus J&J's vaccine panel & access for Africa
21 mins; February 22, 2021
Ep. 45 - Start-Up Trends, COVID Variants and J&J's Adcomm
17 mins; February 16, 2021
Ep. 44 - Biotech's IPO blizzard, plus GameStop, Porter Report & Vaccine Guidance
19 mins; February 08, 2021
Ep. 43 - Europe's Next Act & the Porter Report
16 mins; February 01, 2021
Ep. 42 - Warp Speed Reflections, Master Protocols & Biden’s COVID Plan
16 mins; January 25, 2021
Ep. 41 - Biden's Science Team; Plus: Early Cancer Detection
16 mins; January 19, 2021
Ep. 40 - Investors' Picks & Access to Capital in 2021
16 mins; January 14, 2021
Ep. 39 - COVID Accountability, Biden's Bidding & Start-up Season
15 mins; January 11, 2021
Ep. 38 - Crucible of COVID, Ahoy 2021 & Cancer Deal Trends
23 mins; January 04, 2021
Ep. 37 - 2020's Silver Linings, New Year's Hopes
27 mins; December 29, 2020
Special Report: Where the gene editing field is headed A conversation with Sandy Macrae
23 mins; December 18, 2020
Ep. 36 - Vaccines march forward & CAR Ts move earlier: a BioCentury podcast
17 mins; December 14, 2020
Ep. 35 - ASH Monday, Biden's Picks & Vaccine Conundrums
23 mins; December 07, 2020
Ep. 34 - Moderna Moves & Immunocore Breaks Through
19 mins; November 30, 2020
Ep. 33 - ASH Preview & Long Shot Drug Pricing Rule
21 mins; November 23, 2020
Ep. 32 - Moderna Times & China's Future
21 mins; November 16, 2020
Special Report: A Huge Sigh of Relief but a Long Road Ahead
0 secs; November 13, 2020
Ep. 31 - Pfizer & Biogen: The Good, the bAD and What's Next
23 mins; November 09, 2020
Special Report: Where China's Hatch-Waxman Act falls short
0 secs; November 06, 2020
Ep. 30 - ICER's Influence and Election Effects
16 mins; November 02, 2020
Ep. 29 - SPACs & Vax
20 mins; October 26, 2020
Ep. 28 - FDA's Future & China Summit Preview
20 mins; October 20, 2020
Ep. 27 - CRISPR advances and mega-IPOs: a BioCentury podcast
12 mins; October 12, 2020
Ep. 26 - Treating Trump & BMS's $13B MyoKardia buy
19 mins; October 05, 2020
Ep. 25 - Alzheimer Milestones & Vaccine Politics
13 mins; September 28, 2020
Ep. 24 - Azar's Memo & Biotech's Deals
17 mins; September 21, 2020
Ep. 23 - $21B Deal by Gilead, None by PhRMA
11 mins; September 14, 2020
Ep. 22 - Back to School, Behind the Scenes
16 mins; September 08, 2020
Ep. 21 - FDA’s Credibility on the Line, plus Biotech’s Venture Wave
11 mins; August 31, 2020
Ep. 20 - Politics & Plasma
15 mins; August 24, 2020
Ep. 19 - I Want KaNDy, Plus Sputnik V & M&A amid COVID-19
14 mins; August 17, 2020
Ep. 18 - BIOEquality, Data Sharing and Deals
17 mins; August 10, 2020
Special Report: Data Sharing in and After COVID, With Anne Heatherington
26 mins; August 07, 2020
Ep. 17 - Warp Speed, Decentralized Trials & SPACs
16 mins; August 03, 2020
Ep. 16 - Trump's Ultimatum, RADx & Preclinical IPOs
18 mins; July 27, 2020
Ep. 15 - Vaccine Hopes, the Shifting Biopharma Workplace & Blueprint's Dx Deal
16 mins; July 20, 2020
Ep. 14 - Investor Sentiment, HCQ Redux and Attacking AMR
13 mins; July 13, 2020
Special Report: One on One with Sofinnova’s Papiernik
13 mins; July 09, 2020
Ep. 13 - Nuances of NASH, COVID Vaccines and Real-World Data
15 mins; July 06, 2020
Ep. 12 - Remdesivir's Price, RWD’s Moment & A Genomics Breakup
11 mins; June 29, 2020
Special Report: Lessons from the First Wave of COVID-19 Trials
10 mins; June 25, 2020
Ep. 11 - Funding U.K. Biotechs, plus Global Vaccine Access
15 mins; June 22, 2020
Ep. 10 - EUAs, ACTIV & M&A
17 mins; June 15, 2020
Ep. 9 - IPOs, Vaccines & BIO's New Leader
13 mins; June 08, 2020
Ep. 8 - Financing Flurry & Purchasing Pools
13 mins; June 01, 2020
Special Report: 'A Science Problem We Can Solve' with George Scangos and Hal Barron
35 mins; May 28, 2020
Ep. 7 - FDA takes on COVID-19, plus ASCO's breakthroughs
15 mins; May 26, 2020
Special Report: Deal Flow, Diagnostics and Defeating COVID-19
25 mins; May 20, 2020
Ep. 6 - New Faces for COVID-19’s Next Phase, ASCO’s Hot Topics
18 mins; May 18, 2020
Special Report: In Conversation with New BIO CEO Michelle McMurry-Heath
17 mins; May 15, 2020
Special Report: Collaborating Against the Challenges of COVID Part 2: A conversation with NBIR President Jay Bradner
21 mins; May 13, 2020
Special Report: Collaborating Against the Challenges of COVID Part 1: A conversation with Novartis' John Tsai
20 mins; May 13, 2020
Ep. 5 - Master Protocols, EUAs and Rick Bright: BioCentury editors on COVID-19
15 mins; May 12, 2020
Special Report: Getting Real about COVID-19 Data Part 1: A conversation with Amy Abernethy
21 mins; May 08, 2020
Special Report: Getting Real about COVID-19 Data Part 2: A conversation with Mark McClellan
16 mins; May 08, 2020
Special Report: Consummating a deal under lockdown
25 mins; May 06, 2020
Ep. 4 - End of the beginning for vaccines and the post-pandemic future
15 mins; May 05, 2020
Ep. 3 - Surveying the Landscape for Biopharmas
14 mins; April 28, 2020
Special Report: Interview with FDA Commissioner Stephen Hahn
17 mins; April 27, 2020
Ep. 2 - Consorting to beat COVID-19
14 mins; April 23, 2020
Ep. 1 - Racing to Create Countermeasures
16 mins; April 22, 2020
Click here to see more
Useful pages

Apply to teach

Reviews

Help & FAQs

Blog

Spanish Podcast

French Podcast

Italian Podcast

About Us

Contact Us

Terms & Privacy

Find a tutor

Arabic tutors

Chinese tutors

Dutch tutors

English tutors

French tutors

German tutors

Greek tutors

Italian tutors

Japanese tutors

Korean tutors

Portuguese tutors

Romanian tutors

Russian tutors

Spanish tutors

Swedish tutors

Thai tutors

More languages soon!

Languages

Learn Arabic

Learn Chinese

Learn Dutch

Learn English

Learn French

Learn German

Learn Greek

Learn Italian

Learn Japanese

Learn Korean

Learn Portuguese

Learn Romanian

Learn Russian

Learn Spanish

Learn Swedish

Learn Thai

© 2026 LanguaTalk, All Rights Reserved